---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-006755"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2022-02-24T23:59:59+00:00"
generated_at: "2026-06-27T04:54:45.555353+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AbCellera FY2021 revenue $375M (+61% YoY); EPS $0.56; 26 new program starts

## Summary
- Total revenue $375.2M (up 61% from $233.2M in 2020), driven by $327.3M in royalty revenue.
- Net earnings $153.5M ($0.56 basic EPS) vs. $118.9M ($0.53) in 2020; diluted EPS $0.48.
- Ended year with $723M in cash and marketable securities; 26 new program starts (78 cumulative).
- Q4 revenue $139.3M (37% of FY total), net earnings $59.9M ($0.21 basic EPS).
- Five molecules now in clinic (up from one); acquired TetraGenetics for transmembrane protein targets.

## SEC filing metadata
- accession: 0001564590-22-006755
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2022-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000156459022006755/0001564590-22-006755-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000156459022006755/abcl-8k_20220224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-006755
- JSON: https://secwatch.observer/filing/0001564590-22-006755.json
- Plain text: https://secwatch.observer/filing/0001564590-22-006755.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.